177lu-psma-617,olaparib
novartis,merck,astrazeneca
['luparp', 'olaparib']
#asco2023 a/prof shahneen sandhu presenting luparp data. combination lu psma -617 + olaparib phase 1 trial
well tolerated with no dlt. early data psa 50%rr 66% overall and 75% at peak dose. great translational work. 
Theranostics and nuclear medicine specialist @SVHSydney
@anzuptrials groupie. PET imaging and therapy trials for precision medicine and improving outcomes.